-
Media ReleaseNovartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media ReleaseNovartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media ReleaseNovartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media ReleaseNovartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media ReleaseNovartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media ReleaseImportant new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media ReleaseAlcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media ReleaseNovartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
-
Media ReleaseAlcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media ReleaseNovartis out-licenses three COPD products in the US
-
Media ReleaseNovartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL